Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys. (scientific article published in September 2004)

HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region

Q28252310

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

Q29619980

Cellular uptake of the tat protein from human immunodeficiency virus

Q29620627

Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques.

Q30329383

Tat protein induces human immunodeficiency virus type 1 (HIV-1) coreceptors and promotes infection with both macrophage-tropic and T-lymphotropic HIV-1 strains

Q33785321

Simian immunodeficiency virus disease course is predicted by the extent of virus replication during primary infection.

Q33813926

The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1-infected individuals

Q34104267

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

Q34105993

The trans-activator gene of HTLV-III is essential for virus replication

Q34161962

Unintegrated circular HIV-1 DNA in the peripheral mononuclear cells of HIV-1-infected subjects: association with high levels of plasma HIV-1 RNA, rapid decline in CD4 count, and clinical progression to AIDS.

Q50629542

Selective transcription and modulation of resting T cell activity by preintegrated HIV DNA.

Q51964201

Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia

Q57075698

Design and In Vivo Immunogenicity of a Polyvalent Vaccine Based on SIVmac Regulatory Genes

Q57089569

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

Q59511395

NOVEL STRATEGIES TOWARD THE DEVELOPMENT OF AN EFFECTIVE VACCINE TO PREVENT HUMAN IMMUNODEFICIENCY VIRUS INFECTION OR ACQUIRED IMMUNODEFICIENCY VIRUS*

Q61641127

The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1-infected women: results of the women's interagency HIV study

Q73048874

Persistence of episomal HIV-1 infection intermediates in patients on highly active anti-retroviral therapy

Q73308229

Tat-vaccinated macaques do not control simian immunodeficiency virus SIVmac239 replication

Q34336210

Rational development of prophylactic HIV vaccines based on structural and regulatory proteins

Q34416398

Location of the trans-activating region on the genome of human T-cell lymphotropic virus type III.

Q34564460

The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes

Q34619970

Tat-mediated delivery of heterologous proteins into cells

Q34991904

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys

Q35885915

Interferon alpha and Tat involvement in the immunosuppression of uninfected T cells and C-C chemokine decline in AIDS.

Q36011366

Determinant of HIV-1 mutational escape from cytotoxic T lymphocytes

Q36370382

Epitopes for natural antibodies of human immunodeficiency virus (HIV)-negative (normal) and HIV-positive sera are coincident with two key functional sequences of HIV Tat protein

Q36486560

The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection

Q36548993

Regulatory pathways governing HIV-1 replication

Q38360638

A pathogenic threshold of virus load defined in simian immunodeficiency virus- or simian-human immunodeficiency virus-infected macaques

Q39583691

Outcome of simian-human immunodeficiency virus strain 89.6p challenge following vaccination of rhesus macaques with human immunodeficiency virus Tat protein

Q39683362

Plasma viremia in macaques infected with simian immunodeficiency virus: plasma viral load early in infection predicts survival.

Q39877649

Unintegrated HIV-1 circular 2-LTR proviral DNA as a marker of recently infected cells: relative effect of recombinant CD4, zidovudine, and saquinavir in vitro

Q40952892

Induction of apoptosis in uninfected lymphocytes by HIV-1 Tat protein

Q41349382

Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi's sarcoma

Q41435232

Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients

Q41734588

Vaccination with Rev and Tat against AIDS.

Q42543092

Circular viral DNA and anomalous junction sequence in PBMC of HIV-infected individuals with no detectable plasma HIV RNA.

Q43508525

Inhibition of antigen-induced lymphocyte proliferation by Tat protein from HIV-1.

Q43692324

Speed of progression to AIDS and degree of antibody response to accessory gene products of HIV-1.

Q43984746

Micellar-type complexes of tailor-made synthetic block copolymers containing the HIV-1 tat DNA for vaccine application

Q43991991

Tat protein is an HIV-1-encoded beta-chemokine homolog that promotes migration and up-regulates CCR3 expression on human Fc epsilon RI+ cells

Q44362243

Viral DNA burden and decline in percentage of CD4-positive cells in the lymphoid compartment of SIV-infected macaques

Q44731441

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

Q45012988

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

Q45710857

Acute phase cytotoxic T lymphocyte escape is a hallmark of simian immunodeficiency virus infection

Q45732713

Regulation of Cellular Gene Expression and Function by the Human Immunodeficiency Virus Type 1 Tat Protein

Q45734648

Longitudinal human immunodeficiency virus type 1 load in the italian seroconversion study: correlates and temporal trends of virus load

Q45747378

Live attenuated simian immunodeficiency virus prevents super-infection by cloned SIVmac251 in cynomolgus monkeys

Q45759814

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

Q45761033

Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).

Q45838520

Antibodies against full-length Tat protein and some low-molecular-weight Tat-peptides correlate with low or undetectable viral load in HIV-1 seropositive patients

Q47216468

Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients

Q47918537

P433

issue

25-26

P407

language of work or name

English

Q1860

P304

page(s)

3258-3269

P577

publication date

2004-09-01

P1433

published in

Vaccine

Q7907941

P1476

title

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys

P478

volume

Reverse relations

cites work (P2860)

Q37054470	A HIV-Tat/C4-binding protein chimera encoded by a DNA vaccine is highly immunogenic and contains acute EcoHIV infection in mice
Q44280840	A combination HIV vaccine based on Tat and Env proteins was immunogenic and protected macaques from mucosal SHIV challenge in a pilot study.
Q38289113	A critical analysis of the cynomolgus macaque, Macaca fascicularis, as a model to test HIV-1/SIV vaccine efficacy
Q35785031	A replication-competent adenovirus-human immunodeficiency virus (Ad-HIV) tat and Ad-HIV env priming/Tat and envelope protein boosting regimen elicits enhanced protective efficacy against simian/human immunodeficiency virus SHIV89.6P challenge in rhe
Q92906228	Anti-Tat Immunity in HIV-1 Infection: Effects of Naturally Occurring and Vaccine-Induced Antibodies Against Tat on the Course of the Disease
Q27333734	Biocompatible anionic polymeric microspheres as priming delivery system for effetive HIV/AIDS Tat-based vaccines
Q34148683	Challenges in HIV Vaccine Research for Treatment and Prevention
Q61641053	Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin
Q36961218	Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infection
Q46860089	Core-shell microspheres by dispersion polymerization as promising delivery systems for proteins
Q37967232	Current status and perspectives of plant-based candidate vaccines against the human immunodeficiency virus (HIV).
Q38533881	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine
Q48036553	Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers
Q42061242	Effects of different routes of administration on the immunogenicity of the Tat protein and a Tat-derived peptide
Q61641083	Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag
Q44722017	Exploratory clinical studies of a synthetic HIV-1 Tat epitope vaccine in asymptomatic treatment-naïve and antiretroviral-controlled HIV-1 infected subjects plus healthy uninfected subjects
Q35946931	Fruit-specific expression of the human immunodeficiency virus type 1 tat gene in tomato plants and its immunogenic potential in mice.
Q30381447	HIV-1 Tat-based vaccines: an overview and perspectives in the field of HIV/AIDS vaccine development.
Q34477471	HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies
Q30404393	Human immunodeficiency virus (HIV) immunopathogenesis and vaccine development: a review
Q34055475	Impact of viral dose and major histocompatibility complex class IB haplotype on viral outcome in mauritian cynomolgus monkeys vaccinated with Tat upon challenge with simian/human immunodeficiency virus SHIV89.6P
Q81034939	Increasing the humoral immunogenic properties of the HIV-1 Tat protein using a ligand-stabilizing strategy
Q42930401	Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope
Q33739129	Induction of antibodies and T cell responses by a recombinant influenza virus carrying an HIV-1 TatΔ51-59 protein in mice
Q47738688	Induction of humoral and enhanced cellular immune responses by novel core-shell nanosphere- and microsphere-based vaccine formulations following systemic and mucosal administration
Q39708894	Interferon regulatory factor-1 acts as a powerful adjuvant in tat DNA based vaccination.
Q37153763	Molecular and Genetic Characterization of HIV-1 Tat Exon-1 Gene from Cameroon Shows Conserved Tat HLA-Binding Epitopes: Functional Implications
Q44189653	Multi-envelope HIV-1 vaccine devoid of SIV components controls disease in macaques challenged with heterologous pathogenic SHIV.
Q34579037	Novel biopanning strategy to identify epitopes associated with vaccine protection
Q38086871	Peptides as the next generation of anti-infectives.
Q51828622	Phase I therapeutic trial of the HIV-1 Tat protein and long term follow-up.
Q60243630	Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes
Q36758574	Problems and emerging approaches in HIV/AIDS vaccine development
Q36424574	Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses
Q34488930	Reservoir cells no longer detectable after a heterologous SHIV challenge with the synthetic HIV-1 Tat Oyi vaccine.
Q38877236	Tat mutations in an African cohort that do not prevent transactivation but change its immunogenic properties
Q56897975	Tat protein vaccination of cynomolgus macaques influences SHIV-89.6P cy243 epitope variability
Q61641064	The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS
Q34756847	The grafting of universal T-helper epitopes enhances immunogenicity of HIV-1 Tat concurrently improving its safety profile
Q38378021	The preventive phase I trial with the HIV-1 Tat-based vaccine
Q28476094	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART
Q33984182	Vectored Gag and Env but not Tat show efficacy against simian-human immunodeficiency virus 89.6P challenge in Mamu-A*01-negative rhesus monkeys
Q37220038	What does the structure-function relationship of the HIV-1 Tat protein teach us about developing an AIDS vaccine?

P356	DOI	10.1016/J.VACCINE.2004.03.009
P698	PubMed publication ID	15308348
P5875	ResearchGate publication ID	8403626